Literature DB >> 17525715

The genetics of IgA nephropathy.

Isabel Beerman1, Jan Novak, Robert J Wyatt, Bruce A Julian, Ali G Gharavi.   

Abstract

IgA nephropathy is the most common form of primary glomerulonephritis. Variations in clinical manifestations indicate that a diagnosis of IgA nephropathy encompasses multiple disease subsets that cannot be distinguished on the basis of renal pathology or clinical variables alone. Familial forms of the disease have been reported throughout the world, but are probably under-recognized because associated urinary abnormalities are often intermittent in affected family members. IgA nephropathy has complex determination, with different genes probably causing disease in different patient subgroups. Of the many pathogenic mechanisms reported, defects in IgA1 glycosylation that lead to formation of immune complexes have been consistently implicated. Here, we present the evidence for genetic contributions to the disease, review clinical patterns of familial disease, and summarize some of the most promising genetic studies conducted to date. Linkage-based approaches to the study of familial forms of the disease have identified significant or suggestive loci on chromosomes 6q22-23, 2q36, 4q26-31, 17q12-22 and 3p24-23, but no causal gene has yet been identified. Many interesting, but poorly replicated, genetic association studies have also been reported. We discuss recent developments in analytic tools that should enable genetic studies of sporadic forms of disease by the genome-wide association approach.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17525715     DOI: 10.1038/ncpneph0492

Source DB:  PubMed          Journal:  Nat Clin Pract Nephrol        ISSN: 1745-8323


  25 in total

Review 1.  Glomerular diseases: genetic causes and future therapeutics.

Authors:  Chih-Kang Chiang; Reiko Inagi
Journal:  Nat Rev Nephrol       Date:  2010-07-20       Impact factor: 28.314

2.  Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy.

Authors:  Ali G Gharavi; Zina Moldoveanu; Robert J Wyatt; Catherine V Barker; Susan Y Woodford; Richard P Lifton; Jiri Mestecky; Jan Novak; Bruce A Julian
Journal:  J Am Soc Nephrol       Date:  2008-02-13       Impact factor: 10.121

Review 3.  IgG-Fc N-glycosylation at Asn297 and IgA O-glycosylation in the hinge region in health and disease.

Authors:  Jing Xue; Li-Ping Zhu; Qiang Wei
Journal:  Glycoconj J       Date:  2013-06-20       Impact factor: 2.916

Review 4.  Genetics of kidney failure and the evolving story of APOL1.

Authors:  David J Friedman; Martin R Pollak
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

5.  Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy.

Authors:  Grazia Serino; Fabio Sallustio; Sharon N Cox; Francesco Pesce; Francesco P Schena
Journal:  J Am Soc Nephrol       Date:  2012-02-23       Impact factor: 10.121

6.  HLA has strongest association with IgA nephropathy in genome-wide analysis.

Authors:  John Feehally; Martin Farrall; Anne Boland; Daniel P Gale; Ivo Gut; Simon Heath; Ashish Kumar; John F Peden; Patrick H Maxwell; David L Morris; Sandosh Padmanabhan; Timothy J Vyse; Anna Zawadzka; Andrew J Rees; Mark Lathrop; Peter J Ratcliffe
Journal:  J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 10.121

Review 7.  Glycosylation of IgA1 and pathogenesis of IgA nephropathy.

Authors:  Jan Novak; Bruce A Julian; Jiri Mestecky; Matthew B Renfrow
Journal:  Semin Immunopathol       Date:  2012-03-21       Impact factor: 9.623

8.  Genetic contribution and associated pathophysiology in end-stage renal disease.

Authors:  Suraksha Agrawal; Ss Agarwal; Sita Naik
Journal:  Appl Clin Genet       Date:  2010-08-05

Review 9.  Immunopathogenesis of IgAN.

Authors:  Jonathan Barratt; Alice C Smith; Karen Molyneux; John Feehally
Journal:  Semin Immunopathol       Date:  2007-09-13       Impact factor: 9.623

Review 10.  Idiopathic immunoglobulin A nephropathy in children and adolescents.

Authors:  Ronald J Hogg
Journal:  Pediatr Nephrol       Date:  2009-02-05       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.